Drug research
Treatment of K562 Cells with ABL Kinase Inhibitors Reveals Differential Metabolic Profiles.
Pranay Renukuntla, Sai Charitha Mullaguri, Divya Presingu, Rama Krishna Kancha, Jagadeshwar Reddy Thota
Published: 202610.1055/a-2769-1965
Abstract
ABL kinase inhibitors have transformed the clinical management of chronic myelogenous leukemia; yet, the metabolic consequences of their use remain largely unexplored. In the current study, using K562 cell lines, the metabolic impact of five ABL kina…
Preview only. Read the full abstract at the source